Identifying potential inhibitors for wild-type EGFR tyrosine kinase through a cross-talk pathway strategy and an in-silico drug repurposing method
Dorra Abdelmalek, Kawther Bedchich, Fahmi Smaoui, Salim Kraiem, Mohamed Ali Mosrati, Mohamed Sami Aifa · 2026
Read Identifying potential inhibitors for wild-type EGFR tyrosine kinase through a cross-talk pathway strategy and an in-silico drug repurposing method by Dorra Abdelmalek, Kawther Bedchich, Fahmi Smaoui, Salim Kraiem, Mohamed Ali Mosrati, Mohamed Sami Aifa (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0350847.txt.
Description
Dorra Abdelmalek and colleagues went hunting for a new use for old cancer drugs: blocking the normal, non-mutated form of a growth receptor that many tumors lean on. Most approved blockers target mutated versions of the receptor, leaving patients whose tumors use the normal form with few options. From a library of approved kinase drugs first built against another target, computer screening pulled five candidates.
All five fit the receptor's fuel pocket in simulation, and one, labeled D4, gripped the key hinge and switch residues best. A hundred-nanosecond molecular movie showed the pairing held steady, and energy calculations backed it. Everything here is in silico, a ranked shortlist rather than a medicine. Still, repurposing approved compounds starts years ahead of new chemistry, so a credible shortlist is worth the laboratory tests it now invites.
Catalog record
| CREATOR | Dorra Abdelmalek, Kawther Bedchich, Fahmi Smaoui, Salim Kraiem, Mohamed Ali Mosrati, Mohamed Sami Aifa |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47543 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |